Welcome to LookChem.com Sign In|Join Free

CAS

  • or
4,6-Pyrimidinediamine, N-ethyl-N'-[4-(4-methyl-1-piperazinyl)phenyl]- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

872511-29-0

Post Buying Request

872511-29-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

872511-29-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 872511-29-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,2,5,1 and 1 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 872511-29:
(8*8)+(7*7)+(6*2)+(5*5)+(4*1)+(3*1)+(2*2)+(1*9)=170
170 % 10 = 0
So 872511-29-0 is a valid CAS Registry Number.

872511-29-0Downstream Products

872511-29-0Relevant articles and documents

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl- piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

Guagnano, Vito,Furet, Pascal,Spanka, Carsten,Bordas, Vincent,Le Douget, Micka?l,Stamm, Christelle,Brueggen, Josef,Jensen, Michael R.,Schnell, Christian,Schmid, Herbert,Wartmann, Markus,Berghausen, Joerg,Drueckes, Peter,Zimmerlin, Alfred,Bussiere, Dirksen,Murray, Jeremy,Graus Porta, Diana

supporting information; experimental part, p. 7066 - 7083 (2011/12/04)

A novel series of N-aryl-N′-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the b

PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS

-

Page/Page column 207-208, (2008/06/13)

The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 872511-29-0